Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: March 25, 2025 (Events reported March 25-26, 2025)
Reporting Period: Specific transaction dates in late March 2025.
Business Context: The filing reports unregistered sales of equity securities involving the conversion of Series B Convertible Preferred Stock into common stock.
Key Financial Metrics
This filing does not contain general financial statements (revenue, profit, cash flow, or debt). It reports specific capital structure changes:
- Total Preferred Stock Converted: 830 shares of Series B Convertible Preferred Stock.
- Total Stated Value Converted: $913,000.
- Total Common Stock Issued: 608,668 shares.
- Conversion Price: $1.50 per share.
Material Changes
The filing details four distinct conversion transactions executed on March 25 and March 26, 2025:
- March 25: 116 shares of Preferred Stock ($127,600 value) converted to 85,067 common shares.
- March 25: 350 shares of Preferred Stock ($385,000 value) converted to 256,667 common shares.
- March 25: 146 shares of Preferred Stock ($160,600 value) converted to 107,067 common shares.
- March 26: 218 shares of Preferred Stock ($239,800 value) converted to 159,867 common shares.
Regulatory Status: The Company claims an exemption from registration under Section 3(a)(9) of the Securities Act of 1933, as these were exchanges with existing security holders without commission.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the equity transaction.
Investor Verification Checklist
- Verify the total number of outstanding common shares post-conversion to assess dilution impact.
- Confirm the remaining balance of Series B Convertible Preferred Stock.
- Review the Company's cash position to ensure liquidity is unaffected by the non-cash conversion.
- Check for any subsequent filings regarding the impact of these conversions on earnings per share (EPS).